ARTBIO Raises $132M in Series B Financing to Advance Cancer Therapies

ARTBIO, Inc. has closed a Series B financing round, securing $132 million to support the development of its alpha radioligand therapies (ARTs) for cancer treatment. The funding will advance the lead asset AB001 through Phase II development, progress undisclosed programs toward IND readiness, and expand the supply chain using ARTBIO's proprietary generator technology.